GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurologix Inc (GREY:NRGXQ) » Definitions » Debt-to-EBITDA

Neurologix (Neurologix) Debt-to-EBITDA : -0.53 (As of Jun. 2011)


View and export this data going back to . Start your Free Trial

What is Neurologix Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurologix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2011 was $6.08 Mil. Neurologix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2011 was $0.00 Mil. Neurologix's annualized EBITDA for the quarter that ended in Jun. 2011 was $-11.46 Mil. Neurologix's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2011 was -0.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Neurologix's Debt-to-EBITDA or its related term are showing as below:

NRGXQ's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Neurologix Debt-to-EBITDA Historical Data

The historical data trend for Neurologix's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurologix Debt-to-EBITDA Chart

Neurologix Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.52

Neurologix Quarterly Data
Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.64 -0.67 -0.53

Competitive Comparison of Neurologix's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Neurologix's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurologix's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurologix's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Neurologix's Debt-to-EBITDA falls into.



Neurologix Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurologix's Debt-to-EBITDA for the fiscal year that ended in Dec. 2010 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.695 + 0) / -9.092
=-0.52

Neurologix's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2011 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.078 + 0) / -11.46
=-0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2011) EBITDA data.


Neurologix  (GREY:NRGXQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Neurologix Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Neurologix's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurologix (Neurologix) Business Description

Traded in Other Exchanges
N/A
Address
One Bridge Plaza, Fort Lee, NJ, USA, 07024
Neurologix Inc is a development stage company that is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, using gene transfer and other innovative therapies.

Neurologix (Neurologix) Headlines

No Headlines